GeneraLife IVF, Clinica Valle Giulia, 00197 Rome, Italy.
Igenomix, 36063 Marostica, Italy.
Hum Reprod. 2021 Mar 18;36(4):929-940. doi: 10.1093/humrep/deab014.
Is there an association between patients' reproductive history and the mean euploidy rates per biopsied blastocysts (m-ER) or the live birth rates (LBRs) per first single vitrified-warmed euploid blastocyst transfers?
Patients' reproductive history (as annotated during counselling) showed no association with the m-ER, but a lower LBR was reported after euploid blastocyst transfer in women with a history of repeated implantation failure (RIF).
Several studies have investigated the association between the m-ER and (i) patients' basal characteristics, (ii) ovarian stimulation strategy and dosage, (iii) culture media and conditions, and (iv) embryo morphology and day of full blastocyst development. Conversely, the expected m-ER due to women's reproductive history (previous live births (LBs), miscarriages, failed IVF cycles and transfers, and lack of euploid blastocysts among prior cohorts of biopsied embryos) still needs investigations. Yet, this information is critical to counsel new patients about a first cycle with preimplantation genetic testing for aneuploidy (PGT-A), but even more so after former adverse outcomes to prevent treatment drop-out.
STUDY DESIGN, SIZE, DURATION: This observational study included all patients undergoing a comprehensive chromosome testing (CCT)-based PGT-A cycle with at least one biopsied blastocyst in the period April 2013-December 2019 at a private IVF clinic (n = 2676 patients undergoing 2676 treatments and producing and 8151 blastocysts). m-ER were investigated according to women's reproductive history of LBs: no/≥1, miscarriages: no/1/>1; failed IVF cycles: no/1/2/>2, and implantation failures after previous transfers: no/1/2/>2. Among the 2676 patients included in this study, 440 (16%) had already undergone PGT-A before the study period; the data from these patients were further clustered according to the presence or absence of euploid embryo(s) in their previous cohort of biopsied blastocysts. The clinical outcomes per first single vitrified-warmed euploid blastocyst transfers (n =1580) were investigated according to the number of patients' previous miscarriages and implantation failures.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The procedures involved in this study included ICSI, blastocyst culture, trophectoderm biopsy without hatching in Day 3, CCT-based PGT-A without reporting segmental and/or putative mitotic (or mosaic) aneuploidies and single vitrified-warmed euploid blastocyst transfer. For statistical analysis, Mann-Whitney U or Kruskal-Wallis tests, as well as linear regressions and generalised linear models among ranges of maternal age at oocyte retrieval were performed to identify significant differences for continuous variables. Fisher's exact tests and multivariate logistic regression analyses were instead used for categorical variables.
Maternal age at oocyte retrieval was the only variable significantly associated with the m-ER. We defined five clusters (<35 years: 66 ± 31%; 35-37 years: 58 ± 33%; 38-40 years: 43 ± 35%; 40-42 years: 28 ± 34%; and >42 years: 17 ± 31%) and all analyses were conducted among them. The m-ER did not show any association with the number of previous LBs, miscarriages, failed IVF cycles or implantation failures. Among patients who had already undergone PGT-A before the study period, the m-ER did not associate with the absence (or presence) of euploid blastocysts in their former cohort of biopsied embryos. Regarding clinical outcomes of the first single vitrified-warmed euploid blastocyst transfer, the implantation rate was 51%, the miscarriage rate was 14% and the LBR was 44%. This LBR was independent of the number of previous miscarriages, but showed a decreasing trend depending on the number of previous implantation failures, reaching statistical significance when comparing patients with >2 failures and patients with no prior failure (36% versus 47%, P < 0.01; multivariate-OR adjusted for embryo quality and day of full blastocyst development: 0.64, 95% CI 0.48-0.86, P < 0.01). No such differences were shown for previous miscarriage rates.
LIMITATIONS, REASONS FOR CAUTION: The sample size for treatments following a former completed PGT-A cycle should be larger in future studies. The data should be confirmed from a multicentre perspective. The analysis should be performed also in non-PGT cycles and/or including patients who did not produce blastocysts, in order to investigate a putative association between women's reproductive history with outcomes other than euploidy and LBRs.
These data are critical to counsel infertile couples before, during and after a PGT-A cycle, especially to prevent treatment discontinuation due to previous adverse reproductive events. Beyond the 'maternal age effect', the causes of idiopathic recurrent pregnancy loss (RPL) and RIF are likely to be endometrial receptivity and selectivity issues; transferring euploid blastocysts might reduce the risk of a further miscarriage, but more information beyond euploidy are required to improve the prognosis in case of RIF.
STUDY FUNDING/COMPETING INTEREST(S): No funding was received and there are no competing interests.
N/A.
患者的生殖史是否与活检囊胚的平均整倍体率(m-ER)或首次单个冷冻解冻整倍体囊胚移植的活产率(LBR)相关?
患者的生殖史(在咨询期间注明)与 m-ER 无关,但在有反复着床失败(RIF)史的女性中,进行整倍体囊胚移植后的 LBR 较低。
已有多项研究调查了 m-ER 与(i)患者的基础特征,(ii)卵巢刺激策略和剂量,(iii)培养介质和条件,以及(iv)胚胎形态和完全囊胚发育日之间的关系。相反,由于女性的生殖史(先前的活产(LB)、流产、失败的 IVF 周期和转移,以及先前活检胚胎中没有整倍体囊胚)而导致的预期 m-ER 仍需要调查。然而,这些信息对于向新患者咨询首次进行胚胎植入前遗传学检测(PGT-A)的周期非常重要,尤其是在以前的结果不良之后,以防止治疗中断。
研究设计、大小和持续时间:本观察性研究包括在 2013 年 4 月至 2019 年 12 月期间在一家私人 IVF 诊所进行的基于全面染色体检测(CCT)的 PGT-A 周期中至少有一个活检囊胚的所有患者(n=2676 名患者接受了 2676 次治疗,产生了 8151 个囊胚)。m-ER 根据女性的生殖史中的活产情况进行调查:无/≥1,流产:无/1/>1;失败的 IVF 周期:无/1/2/>2,以及先前转移后的着床失败:无/1/2/>2。在这项研究中纳入的 2676 名患者中,有 440 名(16%)在研究期间之前已经接受过 PGT-A;这些患者的数据根据其先前活检囊胚中是否存在整倍体胚胎进行进一步聚类。首次单个冷冻解冻整倍体囊胚移植的临床结局(n=1580)根据患者先前流产和着床失败的数量进行调查。
参与者/材料、设置、方法:该研究涉及 ICSI、囊胚培养、第 3 天未孵化的滋养外胚层活检、基于 CCT 的 PGT-A,不报告片段性和/或推定有丝分裂(或嵌合)非整倍体以及单个冷冻解冻整倍体囊胚移植。为了进行统计分析,对于卵母细胞采集时的母亲年龄,我们使用了 Mann-Whitney U 或 Kruskal-Wallis 检验,以及线性回归和广义线性模型,以确定连续变量的显著差异。对于分类变量,我们使用 Fisher 确切检验和多变量逻辑回归分析。
卵母细胞采集时的母亲年龄是唯一与 m-ER 显著相关的变量。我们定义了五个聚类(<35 岁:66±31%;35-37 岁:58±33%;38-40 岁:43±35%;40-42 岁:28±34%;和>42 岁:17±31%),并在所有这些聚类中进行了分析。m-ER 与先前的活产次数、流产次数、失败的 IVF 周期或着床失败次数均无关联。在研究期间之前已经接受过 PGT-A 的患者中,m-ER 与其先前活检胚胎中是否存在整倍体囊胚无关。关于首次单个冷冻解冻整倍体囊胚移植的临床结局,着床率为 51%,流产率为 14%,活产率为 44%。该活产率不受先前流产次数的影响,但随着先前着床失败次数的增加呈下降趋势,当比较有>2 次失败的患者和无先前失败的患者时,差异具有统计学意义(36%对 47%,P<0.01;多变量-OR 调整了胚胎质量和完全囊胚发育日:0.64,95%CI 0.48-0.86,P<0.01)。但先前流产率无差异。
局限性、谨慎的原因:未来的研究应增加治疗前完成的 PGT-A 周期的样本量。数据应从多中心角度进行证实。还应在非 PGT 周期中进行分析,或者包括未产生囊胚的患者,以调查女性生殖史与整倍体和活产率以外的其他结局之间的潜在关联。
这些数据对于在 PGT-A 周期之前、期间和之后向不孕夫妇提供咨询至关重要,尤其是为了防止由于先前的不良生殖事件而导致治疗中断。除了“母亲年龄效应”之外,复发性妊娠丢失(RPL)和 RIF 的原因可能是子宫内膜容受性和选择性问题;转移整倍体囊胚可能降低进一步流产的风险,但需要更多的信息来改善 RIF 的预后。
研究资金/利益冲突:没有资金来源,也没有利益冲突。
无。